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Abstract 
Introduction: We previously showed that pharmacokinetic-guided prophylaxis (PKP) 
allows the dosing interval to be extended while maintaining a specific trough level. 
However, the associations of peak factor (F) VIII levels and area under the curve (AUC) 
with breakthrough bleeding have not been investigated. 
Aim: Analyze data from the PKP arm to determine whether peak FVIII levels, AUC, and 
time with FVIII levels in a hemostatically effective range are independent predictors of 
bleeding during prophylaxis. 
 Methods: Post hoc analysis of the association of FVIII levels and AUC with annualized 
bleeding rate in 34 patients on PKP. 
Results: During 1 year of PKP, 131 bleeding episodes occurred in 24/34 patients. 
Average peak FVIII levels ranged from 24 to 168 IU/dL, with higher values associated 
with a decreased risk for all bleeding (joint and non-joint; P<0.01) and joint bleeding 
(P<0.01). Following rFVIII infusion, median percent of time spent with FVIII levels >20 
IU/dL was 22%; median AUC was 1363. Both values were significantly associated with a 
lower ABR when targeting a 1% trough at 72 hours. 
Conclusion: When PKP was administered every third day, higher peak FVIII levels, higher 
AUC, and more time spent per week with FVIII levels >20 IU/dL provided increased 
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of variability in individual PK and bleeding risk and support the need for high peak levels 
and AUC in some patients treated every third day. The findings do not necessarily apply 
to alternate-day or other prophylactic dosing regimens. 
Introduction 
Prophylaxis is considered optimal care for children and adults with severe hemophilia A 
[1, 2] because of its proven ability to reduce joint and other bleeding episodes [3-7]. On 
the basis of experience from Sweden, where prophylaxis was pioneered in the late 
1950s [8], target FVIII trough levels for prophylaxis have traditionally been set at ≥1 
IU/dL above baseline, with the intent of converting the severe bleeding phenotype into 
the less frequent bleeding pattern of moderate hemophilia [9]. Yet 1 IU/dL is an 
arbitrary value above which neither all hemorrhages are prevented nor below which 
bleeding inevitably occurs [10, 11]. Some patients, including those with arthropathy or 
who have active lifestyles, may require higher FVIII trough levels [12], while others may 
have trough levels lower than 1 IU/dL but do not bleed [3]. Furthermore, peak FVIII 
levels, area under the curve (AUC), and time spent with FVIII levels >15 IU/dL [13]) may 
also be important in protecting against hemarthroses and other bleeding episodes, 
particularly during periods of high activity, when patients are at increased risk for 
traumatic bleeding. 
 
A “one size fits all” approach to prophylaxis is not necessarily ideal, possibly leading to 
inefficient or unnecessarily costly dosing. Using an individual’s pharmacokinetic (PK) 
response to factor VIII (FVIII) infusions to calculate dose and dosing frequency is one 
strategy for personalizing the prophylactic regimen [12, 14, 15]. In the study of 
prophylaxis with ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin Free 
Method (rAHF-PFM) (NCT00666406), PK-guided prophylaxis (PKP) given every third day 
was comparable to standard weight-based every-other-day prophylaxis (SP) [6]. In both 
arms, the annualized bleeding rate (ABR) [6] and the median annualized joint bleeding 
rate (AJBR) [16] were significantly reduced as compared with on-demand therapy (OD), 
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Here we report the results of a post hoc analysis of data for the intent-to-treat PKP 
group to determine whether peak FVIII levels, AUC, and time with FVIII levels >20 IU/dL 




Clinical study summary 
The details of the rAHF-PFM prophylaxis study (NCT00243386) have been described [6]. 
To summarize, 66 previously on-demand-treated males with moderately severe to 
severe hemophilia A (FVIII ≤2%) aged 7 to 59 years (median: 26 years) who experienced 
≥8 joint hemorrhages in the previous year were treated OD for 6 months. These patients 
(the intent-to-treat population) were then randomly assigned to 12 months of SP (20-40 
IU/kg every other day) or PKP (20-80 IU/kg every third day), with the PKP regimen 
intended to maintain FVIII trough levels ≥1 IU/dL. All prophylactic doses were to be 
infused in the morning. The characteristics of the study patients were similar for the 2 
prophylaxis arms, with all but 1 patient in the SP arm and 2 patients in the PKP arm 
having 1 to 10 target joints (defined as ≥4 bleeds into the same joint within a 6-month 
period or >20 lifetime bleeds into a joint) at the start of prophylaxis. (Five of 32 [16%] 
patients in the SP arm and 13/34 [38%] in the PKP arm had experienced ≥3 joint bleeds 
in the year preceding study randomization.) No information was collected with regard to 
patients’ lifestyle or physical activity. 
 
Median (interquartile range [P25, P75]) ABR during prophylaxis was 1.0 (0.0, 3.5) and 
2.0 (0.0, 6.9) for the SP and PKP arms, respectively, whereas the median ABR (IQR) 
during OD was 43.9 (34.6, 56.5), a statistically significant difference (P<0.0001) [6]. 
Twenty-two patients (33.3%) were hemorrhage-free while receiving prophylaxis (either 
regimen), whereas all patients experienced bleeding during the OD period. Similarly, the 
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hemarthroses; AJBR median: 0.48 [1.96]) or PKP (72 total hemarthroses; AJBR median: 
1.00 [4.07]), as compared with OD (1164 total hemarthroses; AJBR median: 38.65 
[24.81]; P<0.0001) [16].  Median (range) FVIII trough levels were 3.0 IU/dL (0.5-45.0) 
during SP (56 observations in 24 patients) and 1.0 IU/dL (0.5-10.0) during PKP (52 
observations in 23 patients). FVIII consumption and adverse event rates for both 
prophylactic regimens were equivalent, and no patient developed a hypersensitivity 
reaction related to rAHF-PFM or a FVIII inhibitor while on study.  
 
Data for all 34 patients in the every third day intent-to-treat PKP arm were evaluated. A 
total of 4089 prophylactic infusions were administered during a median of 364 
treatment days (range: 97–394). The median dose per infusion was 43.0 (range: 13.0–
107.1) IU/ kg, and the median number of units administered per patient was 2979 
(range: 1073-5600). Bleeding episodes were recorded in patient diaries and verified by 
the investigator. Data collected included time and date of bleeding, anatomical site(s), 
identification of bleeding as joint or non-joint, etiology (spontaneous, traumatic, or 
undetermined), and severity. 
 
Statistical analyses 
The predicted concentration level (IU/dL) at the time of bleeding was projected on the 
basis of individual PK parameters, assuming that each patient was at his natural 
baseline. Average peak FVIII levels were estimated using individual in vivo recovery 
values and average dose/prophylactic infusion.  
 
A negative binomial multivariate regression model was used to evaluate the association 
between ABR and 1) average peak FVIII level (IU/dL), 2) time spent >20 IU/dL FVIII 
activity (%), and 3) weekly AUC (IU x hr/dL); age and body mass index were covariates 
[17]. ABR was calculated as the number of bleeding events divided by the length (in 
years) of the treatment regimen. Average peak FVIII level was calculated as the average 
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spent and weekly AUC above 5, 10, 15, 20, 30, and 40 IU/dL FVIII activity were estimated 
from each patient’s infusion log and time per week together with his PK parameters. 
Correlation between 2 variables was described using nonparametric spearman method.  
 
Results 
A total of 845 bleeding episodes (188 traumatic, 657 spontaneous; 750 joint, 95 non-
joint) occurred in the 34 patients during 6 months of OD that preceded PKP. The mean ± 
SD (range; median) ABR and AJBR during on-demand treatment was 49.2 ± 20.7 (13-
90.8; 44.8) and 43.5 ± 21.3 (6.5-90.8; 39.0), respectively.  
 
Number of hemorrhages and time of bleeding 
During PKP, 131 bleeding episodes occurred in 24/34 patients (70.6%). Among the 121 
episodes of joint bleeding, 4 (all spontaneous) occurred within the first 12 hours after 
infusion, 20 (6 spontaneous) occurred 12-24 hours post-infusion, 49 (21 spontaneous) 
occurred 24-48 hours post-infusion, and 40 (20 spontaneous) occurred 48-72 hours 
post-infusion (Table 1).  No significant increase was observed in the number of bleeding 
episodes occurring more than 48 hours after infusion as compared with those occurring 
within the first 48 hours.  
 
Pattern of spontaneous and traumatic bleeding 
The median predicted concentration (range) at the time of bleeding among patients in 
the PKP arm was 2.71 IU/dL (0-26.55) for 57 spontaneous hemorrhages, 3.57 IU/dL (0-
41.6) for 74 traumatic hemorrhages, 3.43 IU/dL (0-41.67) for 121 hemarthroses, and 
2.87 IU/dL (0-11.26) for 10 non-joint bleeding events (Figures 1 and 2). No statistically 
significant difference in predicted FVIII levels was observed either between spontaneous 
or traumatic or joint and non-joint hemorrhages. Traumatic joint bleeding occurred with 
predicted FVIII levels as high as 42%, but most hemarthroses occurred at levels <10 
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Peak levels and bleeding risk 
Average peak FVIII levels (IVR x average dose) in the PKP arm ranged from 24.3 to 
167.5% (median: 70.9%), with lower values associated with an increased risk for all 
bleeding (P=0.0004) and joint bleeding (P=0.0013) (Figure 3).  
 
AUC and peak FVIII levels in non-bleeding and bleeding patients  
The average predicted AUC was 136 between 24-48 hours and 33 between 48-72 hours 
post-infusion. To further examine the possible relationship between high AUC, peak 
FVIII levels, and bleeding risk in the immediate hours following infusion, we compared 
the weekly AUC 0-12 hours post-infusion for patients who did and did not report 
bleeding (Table 3). No significant difference was observed between the 2 groups, likely 
attributable to the small sample size. Nonetheless, patients who had no bleeding during 
the 12-month study period appeared to have higher post-infusion AUC 0-12 hours as 
well as higher peak FVIII levels. 
 
Time spent at FVIII levels >20 IU/dL and bleeding risk 
Among patients in the PKP arm, the median percent of time spent with FVIII levels >20 
IU/dL was 22.3% (range: 2.9-46.1), resulting in a median AUC of 1363 (range: 130-4265). 
Both values were significantly associated with a lower ABR, and during the period that 
the FVIII concentration was ≥27 IU/dL, PKP-treated patients experienced no 
spontaneous bleeding. This relationship was even more pronounced when a higher 
percentage of time was spent with FVIII levels >30 IU/dL (Figure 4) or higher peak levels 
(Figures 1 and 2) were achieved. The modeled data showed a consistent and strong 
positive correlation among peak level, time above percent, and weekly AUC (Table 2).  
 
Discussion 
In this post hoc analysis of the rAHF-PFM prophylaxis study data, patients receiving PKP 
every third day were dosed to maintain a target trough FVIII level of ≥1 IU/dL [6], 
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Evaluating PK parameters in relation to the reported bleeding events led to 3 
observations. First, higher peak FVIII levels and AUC provided increased protection 
against joint and non-joint bleeding. Specifically, spontaneous bleeding was prevented 
when patients in the PKP arm had a FVIII concentration ≥27 IU/dL.  
 
Broderick and colleagues similarly recognized the link between high peak levels and a 
reduction in bleeding [18]. In a case-crossover study nested within a prospective cohort 
study that included 104 children and adolescents with hemophilia, they found the 
transient increase in bleeding risk associated with vigorous physical activity was 
mitigated with estimated peak factor concentrations of 70 to 100 IU/dL. Conversely, low 
peak levels may have contributed to the increase in bleeding events observed by 
Lindvall et al in some patients who crossed over to daily low-dose prophylaxis designed 
to maintain at least the same FVIII trough level as obtained with their standard 
prophylactic regimens [19].  
 
Second, ABR declined as the percent of time spent weekly with FVIII levels >20-30 IU/dL 
rose. Specifically, among 8 patients who spent ≥20% of time about 30 IU/dL, only 2 had 
an ABR >2. Nearly 40 years ago, Aronstam described a 60% reduction in bleeding 
frequency in boys with severe hemophilia A treated with FVIII-containing “materials” to 
increase their factor levels to 15% to 30% of normal [20]. In 2011, den Uijl observed that 
patients with hemophilia A who had a baseline FVIII activity exceeding 15 IU/dL 
experienced no joint bleeding [13]. This result is not directly equivalent to the situation 
observed in our study, however, as a steady state of 15 IU/dL differs from the peaks and 
troughs we described. Additionally, our FVIII level data are modeled on the basis of 
estimated PK parameters and patient-reported infusion and bleed event (including 
etiology) records, which may introduce some degree of error. Nevertheless, Broderick 
also noted the connection between higher FVIII levels and bleed reduction, reporting 
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When factor levels were maintained at approximately 50 IU/dL during physical activity, 
bleeding risk was lower than that for inactive patients treated on-demand. 
  
Finally, while traumatic bleeding occurred throughout the range of predicted FVIII 
plasma levels (as high as 58 IU/dL), most occurred at FVIII levels <10 IU/dL. These 
observations are consistent with those reported by den Uijl [13]. 
 
In patients with hemophilia A, joint bleeding results in increased morbidity, decreased 
health-related quality of life, and higher treatment costs associated with the 
management of chronic arthropathy [21-24].  Prophylaxis is highly effective in 
preventing joint and other serious bleeding episodes [3-6, 25], but a personalized 
approach to treatment [15] that takes into consideration an individual’s PK—FVIII peaks 
and AUC as well as troughs—may have the potential to optimize the treatment regimen. 
 
It is important to recognize that the findings from our analyses are specific to patients 
with severe hemophilia A (baseline FVIII ≤2%) receiving PKP administered every third 
day. The results cannot necessarily be extrapolated to other regimens and may not be 
applicable to alternate-day dosing. Indeed, we have previously reported that AUC was 
not associated with breakthrough bleeds in patients receiving prophylaxis 3 to 4 times 
per week [26]. Furthermore, , almost all patients had pre-existing joint disease, with 
nearly 40% having ≥3 target joints at study initiation. The impact of joint status on FVIII 
levels at the time of bleeding is unclear. Finally, consistent with the results of den Uijl et 
al [13], the influence of peak FVIII levels is likely to diminish as baseline FVIII levels 
approach the normal range. 
 
The observation that lower peak levels were associated with increased bleeding in the 
PKP arm has interesting implications. Patients with the longest-half-lives required the 
lowest FVIII doses to sustain a level >1 IU/dL by 72 hours and, therefore, also had the 
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well on every third day prophylaxis targeted at a trough of 1 IU/dL than did those with 
shorter half-lives. In addition, owing to the shape of the PK curves in people with longer 
half-lives, those with lower peaks also spent more time with low FVIII levels between 
infusions. Whether these findings have implications for more frequent dosing intervals 
and/or for treatment with extended half-life molecules require further investigation. 
 
Limitations to the analysis 
Our analysis has several limitations. First, the data set is comprised of only 34 patients 
receiving PKP, and the analysis was performed post hoc. Second, information about FVIII 
activity at the time of each bleeding episode was extrapolated from PK data obtained at 
study entry and was calculated using patient-reported time of infusion and time of 
hemorrhage without adjustment for potential residual FVIII from prior dose. Third, the 
impact of a patient’s lifestyle and participation in sports activities on bleeding could not 
be ascertained, as these data were not collected, but it is possible that they may have 
influenced bleeding in some patients. Finally, the possibility that some joint pain-related 
events may have been misclassified as hemarthroses, and that some  bleeding episodes 
may not have been recognized or were misclassified as traumatic (versus spontaneous) 
cannot be ruled-out.  
 
In conclusion, the findings from this post hoc analysis of data for the PKP arm of the 
rAHF-PFM prophylaxis study add to previous observations that time spent with FVIII 
levels <1% positively correlates with bleeding risk by demonstrating that in patients 
receiving every third day prophylaxis targeting a trough of 1 IU/dL, peak FVIII levels, 
AUC, and time spent at high FVIII plasma levels are also associated with the risk for joint 
and non-joint bleeding. The data highlight the potential impact of variability in individual 
PK and the likelihood for hemorrhage and may support the need for higher peak levels 
and AUC in some patients on every third day dosing, such as those with underlying joint 
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Table 1. Number of hemorrhages (patients) and time at which bleeding occurred post-
infusion in the PKP arm.  
 
Bleeding Type 12 hr 12-24 hr 24-48 hr 48-72 hr >72 hr* All 
Spontaneous 4 (4) 7 (4) 21 (13) 22 (12) 3 (3) 57 
Traumatic 0 (0) 14 (9) 31 (10) 22 (11) 7 (4) 74 
Joint 4 (4) 20 (11) 49 (17) 40 (15) 2 (1) 121 
Non-joint 0 (0) 1 (1) 3 (2) 4 (3) 2 10 
*Indicates non-adherence to the treatment regimen. 
Table 2. Average peak level, time above %, and weekly AUC covariance in the PKP 
arm: correlation coefficients among the variables. 
 
Variable PKP (N=34) 
Time >5%                                                         AUC >5% 
Time >10%                                                      AUC >10% 
Time >20%                                                      AUC >20% 
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Time >40%                                                      AUC >40% 
Average Peak 
(IU/dL) 








                             0.82 (s) 
                               0.82 (s) 
                              0.87 (s) 
                               0.94 (s) 
                              0.95 (s)        
 







Not applicable                               0.60 (s) 
                              0.81 (s) 
                              0.90 (s) 
                               0.99 (s)        
0.99 (s) 
 
Non-parametric correlation coefficient: (s) indicates P <0.05. 
Table 3. Peak FVIII and AUC levels within 12-hours post-infusion in non-bleeding and 
bleeding patients  
 
 Non-Bleeding Patients (N=9) Bleeding Patients (N=25) P-value* 
 Min Q25 Median Q75 Max Min Q25 Median Q75 Max  
Average Peak FVIII  
(IU/dL) 
 
45.9 66.9 83.6 124.4 150.9 24.3 45.9 56.4 108.3 167.5 0.4793 
Weekly AUC for 12 
hr after infusion 
 
852.2 1134.5 1263.0 1846.0 2882.0 490.3 774.5 1097.5 1712.1 2353.4 0.3765 
*P-value is from t-test. 
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Figure 2. Joint/non-joint bleeding episodes over time in patients on PKP. 
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The trend curve presents the predicted ABR derived from the negative binomial multivariate regression 
model across the average peak FVIII level for an average patient (with regard to age and body mass 
index).The average peak FVIII levels are related to the risk of all bleeding (P=0.0004; coeff: -0.02) and joint 
bleeding (P=0.0013; coefficient: -0.02).  Four quadrants are identified to signify the relationship between 
bleeding rates and average peak FVIII levels. The horizontal line represents median ABR (2.0) for the 
overall population, and the vertical line represents median theoretical peak FVIII level achieved following 
prophylactic infusion. 
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